D59.31: Infection-associated hemolytic-uremic syndrome
D59.31, infection-associated hemolytic-uremic syndrome, is listed as a covered diagnosis in 5 Medicare billing and coding articles that apply to 5 HCPCS Level II codes, including J1299 (Injection, eculizumab, 2 mg), Q5151 (Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg), Q5152 (Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg). The articles come from 5 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.
HCPCS Level II codes with D59.31 as a covered diagnosis
| Code | Description | Medicare coverage | DMEPOS fee 2026 (state range) | Articles listing it |
|---|---|---|---|---|
| J1299 | Injection, eculizumab, 2 mg | Carrier judgment | — | 1 |
| Q5151 | Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg | Carrier judgment | — | 1 |
| Q5152 | Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg | Carrier judgment | — | 1 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Carrier judgment | — | 4 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | Carrier judgment | — | 4 |
Medicare policy articles listing D59.31
- A54548: Billing and Coding: Eculizumab, and Biosimilars: EPYSQLI®-eculizumab-aagh, and BKEMV™-eculizumab-aeeb (Wellpoint Federal (MAC - Part A, MAC - Part B); 3 Level II codes)
- A58710: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (Palmetto GBA (MAC - Part A, MAC - Part B); 2 Level II codes). LCD with the same title: L38988, L39001, L39038, L39044
- A58720: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (Noridian Healthcare Solutions, LLC (MAC - Part A, MAC - Part B); 2 Level II codes). LCD with the same title: L38988, L39001, L39038, L39044
- A58761: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (WPS Insurance Corporation (MAC - Part A, MAC - Part B); 2 Level II codes). LCD with the same title: L38988, L39001, L39038, L39044
- A58747: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (CGS Administrators, LLC (MAC - Part A, MAC - Part B); 2 Level II codes). LCD with the same title: L38988, L39001, L39038, L39044
A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.
Other D59 diagnoses (Acquired hemolytic anemia)
- D59.30 — Hemolytic-uremic syndrome, unspecified
- D59.0 — Drug-induced autoimmune hemolytic anemia
- D59.10 — Autoimmune hemolytic anemia, unspecified
- D59.11 — Warm autoimmune hemolytic anemia
- D59.12 — Cold autoimmune hemolytic anemia
- D59.13 — Mixed type autoimmune hemolytic anemia
- D59.19 — Other autoimmune hemolytic anemia
- D59.9 — Acquired hemolytic anemia, unspecified
Frequently asked questions
Does Medicare cover D59.31 (Infection-associated hemolytic-uremic syndrome)?
Medicare covers items and services, not diagnoses. 5 Medicare billing and coding articles list D59.31 as a covered diagnosis for 5 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.
Which HCPCS codes can be billed with ICD-10 D59.31?
The Level II codes from the policies most specific to this diagnosis are J1299 (Injection, eculizumab, 2 mg, 1 article); Q5151 (Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg, 1 article); Q5152 (Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg, 1 article); U0002 (2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19)…, 4 articles); U0001 (Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr…, 4 articles). Code choice depends on the item supplied; check each code's descriptor.
Which Medicare policy articles list D59.31?
A54548 (Billing and Coding: Eculizumab, and Biosimilars: EPYSQLI®-eculizumab-aagh, and BKEMV™-eculizumab-aeeb); A58710 (Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing); A58720 (Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing), and 2 more articles.
What is ICD-10-CM code D59.31?
D59.31 is the ICD-10-CM code for infection-associated hemolytic-uremic syndrome, in category D59 (Acquired hemolytic anemia), chapter 3: Diseases of the blood and immune mechanism.
Next steps
- Run a reimbursement report for a device billed under J1299
- Watch J1299 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J1299
Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.
Chapter 3: Diseases of the blood and immune mechanism · All diagnoses · HCPCS lookup